While human chorionic gonadotropin (hCG) appears to have an essential role in early pregnancy, it 32 is controversial whether the hyperglycosylated form of hCG (hCG-h), which is the major hCG 33 isoform during the first 4-5 weeks of pregnancy, is able to activate LH/hCG receptor (LHCGR). To 34 address this, we utilized different extensively characterized hCG and hCGβ reference reagents, cell 35 culture-and urine-derived hCG-h preparations, and an in vitro reporter system for LHCGR 36 activation. The WHO hCG reference reagent (99/688) was found to activate LHCGR with an EC 50 -37 value of 3.3 ± 0.6 pmol/L (n=9). All three studied hCG-h preparations were also able to activate 38 LHCGR, but with a lower potency (EC 50 -values between 7.1 ± 0.5 and 14 ± 3 pmol/L, n=5-11, for 39 all P < 0.05 as compared to the hCG reference). The activities of commercial urinary hCG 40 (Pregnyl) and recombinant hCG (Ovitrelle) preparations were intermediate between those of the 41 hCG reference and the hCG-h. These results strongly suggest that the hCG-h is functionally similar 42 to hCG, although it has lower potency for LHCGR activation. Whether this explains the reduced 43 proportion of hCG-h to hCG reported in patients developing early onset pre-eclampsia or those 44 having early pregnancy loss remains to be determined. 45 46 Keywords: hCG; hyperglycosylated hCG; LHCGR; LH/hCG receptor; reporter system 47 48 1 Abbreviations: cAMP, cyclic adenosine monophosphate; hCG, human chorionic gonadotropin; 49 hCGβ, free β-subunit of hCG; hCGβn nicked hCGβ; hCGβcf, hCGβ core fragment; hCG-h, 50 hyperglycosylated hCG; LHCGR, LH/hCG receptor; LH, luteinizing hormone 51
Technologies) the proteins were transferred to polyvinylidene difluoride membranes, blocked 135 overnight at 4°C with 1% BSA in 50 mmol/L Tris-buffered saline (TBS), pH 7.7, and with 3% milk 136 powder in TBS at room temperature for one hour. The primary antibody against hCGβ (A0231, 137 DAKO, Glostrup, Denmark) in 3% milk powder in TBS was incubated with the membrane for two 138 hours at room temperature. After washing with TBS containing 0.1% Tween, the membrane was 139 incubated with peroxidase-conjugated anti-rabbit IgG (711-035-152, Jackson ImmunoResearch 140
Laboratories, Ely, UK) for one hour at room temperature. After washing, detection was performed 141
with ECL solution (32209, Thermo Fisher Scientific, Rockford, IL). 142 143
LHCGR activation assay 144
For monitoring LHCGR activation we used Madin-Darby Canine Kidney (MDCK) cells stably 145 expressing human LHCGR and quantified receptor-triggered changes in cyclic adenosine 146 monophosphate (cAMP) levels by a Förster resonance energy transfer (FRET) biosensor (33, 36, 147 37). This method allows highly sensitive detection of LHCGR activation, with the limit of detection 148 (LoD) and limit of quantitation (LoQ) for hCG being 0.96 pmol/L and 2.9 pmol/L, respectively. 149 M A N U S C R I P T
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The biosensor expression vector mTurq2∆_Epac(CD,∆DEP)_td cp173 Ven (H188) (38) was kindly 151 provided by Dr. Kees Jalink from the Netherlands Cancer Institute, and modified to be used in 152 BacMam system as previously described (33, 36, 37) . Briefly, the pcDNA3.1+ expression vector 153 with the H188 gene was cloned into the pFastBac™ 1 vector, and the polyhedrin promoter from the 154 pFastBac™ 1 vector was replaced with the powerful mammalian cytomegalovirus promoter. The 155 resulting construct was used to produce bacmid DNA, which was subsequently transfected into 156 Spodoptera frugiperda Sf9 insect cells to obtain the BacMam virus. The virus was amplified, and 157 the stocks stored at -80°C. The viral titers were determined experimentally by a cell size-based 158 assay17 using Sf9 cells (36). The mammalian MDCK cell line used for the measurements was a 159 kind gift from Dr Prema Narayan (Southern Illinois University); the initial cell line had been 160 obtained from ATCC (Manassas, VA) (catalog number CRL 2935). The LHCGR-expressing 161 MDCK cells were grown as adherent monolayers at 37°C and 5% CO 2 in a humidified incubator in 162 Dulbecco's Modified Eagle's Medium and Ham's F-12 nutrient mixture supplemented with 10% 163 fetal bovine serum, 100 U/mL penicillin, 0.1 mg/mL streptomycin and 0.25 µg/mL amphotericin B. 164
165
The assay protocol was adopted from Mazina and coworkers (33, 36, 37), except that LHCGR-166 expressing MDCK cells were used instead of COS-7 cells. Briefly, cells were treated with viral 167 stock (multiplicity of infection: 100-300) in 5 mL of growth medium for 3-4 h at 37°C in a 168 humidified CO 2 incubator. After preincubation with the virus, the medium was aspirated, the cells 169 were trypsinized and resuspended in fresh growth medium containing 10 mM sodium butyrate 170 
Results 230
Since the hCG may exist in many different forms, like nicked hCG, which is common in hCG 231 preparations isolated from urine and has been reported to lack LHCGR stimulating activity, we 232 characterized the preparations used by specific immunoassays for hCG heterodimer, free hCGβ, 233 hCGβcf and hyperglycosylated hCG/hCGβ (Table 1, As expected, hCG activated LHCGR with high efficiency, while hCGβ was devoid of activity or 270 had only residual activity corresponding to the minor hCG contamination in the samples (Table 1,  271 Figure 2, page 13). The EC 50 -value for LHCGR activation by the hCG reference (Table 1 , 272 preparation #1) was 3.3 ± 0.6 pmol/L (mean ± SEM, n=9). All hCG-h preparations (#4, #5 and #6) 273 had lower potency than hCG, the EC 50 -values varying between 7.1 ± 0.5 and 14 ± 3 pmol/L (P < 274 0.05 for all, unpaired t-test with Welch's correction, n= 5-11). The maximal stimulation at high 275 concentrations of hCG (#1-3) and hCG-h (#4-6) were very similar (P > 0.05 for all hCG-h 276 preparations as compared to hCG). Nicked hCG (#7) had relatively low activity (24 ± 6 pmol/L, P < 277 0.05 as compared to the hCG reference), which was compatible with the presence of non-nicked 278 intact hCG in the preparation (Table 1, Figure 1 While hCG appears to have an essential role in early pregnancy, it has remained controversial 318 whether the hyperglycosylated form of hCG, i.e., hCG-h, which is the major isoform of hCG 319 secreted by the placenta during the first 4-5 weeks of pregnancy (17) (18) (19) , is able to activate LHCGR 320 (30, 32, 33). We show here, using highly purified and characterized hCG preparations, that hCG-h 321 activates LHCGR, although with lower potency than non-hyperglycosylated hCG, suggestingM A N U S C R I P T
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16 functional similarity of these two hCG-isoforms, but also that glycosylation may regulate the 323 activity of hCG during early pregnancy. 324
325
The bioactivity of hCG-isoforms has often been studied using cellular systems of non-human 326 species, in which LHCGR is structurally somewhat different from the human receptor (39). For 327 studies on the differences between hCG-isoforms on LHCGR activation, it is important to use an 328 assay utilizing human LHCGR, like the one used in this study. Using this model we showed that all 329 three studied hCG-h preparations had significantly lower potency for LHCGR activation than the 330 WHO hCG reference, which contained about 20% of hCG-h, the rest representing non-331 hyperglycosylated form as detected by specific immunoassays. The hyperglycosylated preparations 332 included early pregnancy, testicular cancer and differentiated stem cell-derived hCG-h, indicating 333 that the lower activity is not limited to a certain hCG-h preparation. As shown previously (5, 6), 334 hCGβ was not able to activate LHCGR. Interestingly, commercial recombinant hCG (Ovitrelle) 335 showed lower activity than the hCG reference and similar trend was observed also for Pregnyl. This 336 may be because of the heterogeneity of Pregnyl, i.e., it contained some hCG-h and nicked hCG, and 337 is known to contain several impurities (31, 40). Ovitrelle seemed to contain two major components, 338 which may represent glycosylation variants. This heterogeneity in SDS electrophoresis has been 339 described also previously (41) and may explain the reduced activity. 340
341
The lower potency of hCG-h for LHCGR activation was supported by our kinetics studies, showing 342 that the effect of hCG-h was slower than that of hCG. Furthermore, we have previously shown that 343 conditioned cell culture medium from human choriocarcinoma JEG-3 cells, which produce hCG-h 344 resembling that from early pregnancy and cancer patients (16), activates LHCGR (33). When this 345 hCG has been enriched from the media by Concanavalin-A lectin-affinity chromatography, it has 346 been found to be less active than non-hyperglycosylated hCG (30). Contrary to these results, it has 347 M A N U S C R I P T
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been reported that purified hCG-h is unable to activate LHCGR, as determined by the lack of 348 induction of progesterone production in luteinized granulosa cells stimulated with hCG-h (32). 349
These earlier discordant results may be explained by differences between various hCG-h 350 preparations, as many of the studies have been compromised by poor characterization of the 351 preparations used. Especially nicking of the hCG, which is common in hCG isoforms isolated from 352 urine (8-10, 42), compromises interpretation of the results. We found that the activity of the nicked 353 hCG reference corresponded and, thus, is likely to be explained by the presence of intact non-354 nicked hCG, which has been estimated to represent 10-15% (43), or even more based on our 355
Western blotting results, of total hCG in this preparation. 356
357
The only apparent difference between hCG-h and hCG is in their glycosylation. In theory, this may 358 affect the tertiary structure of hCG/hCG-h and/or dimer formation with α-subunit, but it is feasible 359 that the glycan(s) are directly responsible for differences in activation of the LHCGR. The variation 360
we observed between different hCG-h preparations may result from variation in glycan structures 361 (16), typical for glycoproteins (44, 45). Previously, the signaling of hCG through LHCGR has been 362 found to be dependent on its glycosylation, e.g., deglycosylated hCG does not induce signaling, 363 although it is able to bind to LHCGR (46, 47). While our results show that hCG-h activates LHCGR 364 less efficiently than hCG, the used reporter system is not able to address whether this is due to the 365 steric effects of glycans in hCG-h decreasing the binding to the receptor or due to decreased signal 366 transduction after the hormone has bound to its receptor. Noteworthy, in our experiments excess of 367 hCGβ did not inhibit the response generated by the hCG reference. This suggests that, unlike 368 deglycosylated hCG, hCGβ does not bind to the LHCGR as also reported previously (5). Especially, 369 the glycan attached to Asn-52 in hCGα appears to be important for LHCGR activation (48) The lower potency of hCG-h to stimulate LHCGR may have (patho)physiological consequences 378 during the first few weeks after the implantation, when hCG-h is the major hCG isoform (17) (18) (19) . 379
Later on, after 4-5 weeks of pregnancy, when hCG-h is still the dominant hCG isoform, its levels 380 are already significantly increased, which may compensate its lower potency in LHCGR activation 381 in corpus luteum and other tissues. This is supported by our observation that maximal activation of 382 LHCGR was similar with both hCG and hCG-h, although higher concentrations of hCG-h were 383 needed for that. During the first weeks of pregnancy, hCG-h is likely to stimulate trophoblast 384 invasion independently of the LHCGR activation (7), but it may also have LHCGR mediated 385 function(s), in addition to corpus luteum, also in uterine and other cells (2). Interestingly, a recent 386 study reported a woman with an inactive mutant LHCGR who maintained a normal pregnancy after 387 becoming pregnant with ovum donation (52) . This suggests that the maintenance of pregnancy 388 through LHCGR activation is not necessary and that during pregnancy the main hCG effect may be 389 mediated by other mechanisms than LHCGR activation. Clinical studies have suggested that low 390 concentrations of hCG-h or low ratio of hCG-h to hCG already on the day of implantation is 391 associated with pregnancy loss (53, 54). However, during that time the levels of hCG-h and hCG 392 are extremely low, making their accurate detection difficult. Contrary to these finding, in IVF 393 treatments it has been found that during the first weeks after embryo transfer the proportion of hCG-394 h to hCG stayed higher in women with early pregnancy loss, as compared to those with a successful 395 IVF pregnancy (55). Later during the first trimester of the pregnancy a reduced proportion of hCG-h 396 to hCG has been found to indicate risk for early onset pre-eclampsia (25). Although these studiesM A N U S C R I P T
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suggest that hCG-h is involved in normal early pregnancy and perhaps also in early onset pregnancy 398 complications, its specific role remains to be established. It is important to note, that the half-life of 399 hCG-h/hCG in circulation and, thereby, the biopotency may also be affected by differences in 400 glycosylation (56). So far, the half-life of hCG-h is not known. 401
402
We have previously shown that when human embryonic stem cells are differentiated into 403 trophoblast-like cells with FGF2 inhibition and BMP4 activation they produce hCG-h (34), which 404 suggests that these differentiated cells are similar to early pregnancy cytotrophoblast cells (18) . 405
Here we report that the hCG-h produced by these differentiated embryonic stem cells is able to 406 activate LHCGR. Thus, this stem cell model would be suitable for studying the function(s) of 407 trophoblast derived hCG-h. 408
409
In conclusion, we showed here that hyperglycosylated hCG is able to activate LHCGR, although 410 with lower potency than hCG. This strongly suggests that the hCG-h is functionally similar to hCG. 411
Whether this explains the reduced proportion of hCG-h to hCG found in patients developing early 412 onset pre-eclampsia or those having early pregnancy loss remains to be determined. -hCG-h has lower potency than hCG for (LHCGR) activation -Kinetics of LHCGR activation was slower with hCG-h than with hCG -Proteolytically processed hCG (hCGβn) had low, if any, potency for LHCGR activation
